See below for the evolving snapshot of the AIS pipeline based on investor slide decks posted to the AIS website (see bottom of each slide for the date it corresponds to)
Most recent changes: February 2011
- Finally have dropped the moribund Jazz gel program for restless leg syndrome off the chart
- Show 2nd Teva Pen product is in clinical trials
- Clarifies ANDA vs NDA 505(b)2 or 505(b)1 pathway for each candidate
- March 2011 presentation accessed 3/14/11: no changes from February slide